Drug intelligence / Profile preview

noramidopyrine

Development stage: Unknown
Modality: Small Molecules
Administration: Oral, Intramuscular

Overview

Noramidopyrine is a pharmaceutical drug classified as a pyrazolone derivative and a non-steroidal anti-inflammatory drug (NSAID). It exhibits analgesic, anti-inflammatory, and antipyretic properties. It is also identified as a marker of metamizole. Noramidopyrine has been used for pain management, including ocular pain, acute pain states, and migraine. However, its use is associated with significant adverse effects such as drug-induced agranulocytosis, acute porphyric neuropathy, and acute interstitial nephritis.

Other names: Metamizol

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on noramidopyrine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on noramidopyrine.

Explore the full profile